#cibmtr search results
Packed room at the #CIBMTR Late Effects working Committee Meeting. Thank you for your participation as we work together to improve HCT survivorship.
#Tandem22 tweeps please support my #CIBMTR proposal on Mantle cell and lines of therapy prior to CAR-T. 👇👍🏼
As my virtual background says... Vote for #CIBMTR proposal n#1 . Risk of subsequent neoplasms(SN) after the use PTCy for GVHD prophylaxis. SN are the leading cause of excess deaths in 5years alloHTC survivors. Its critical we address this question #TCTM21 #TCT #WomenInScienceDay
Now happening: Late breaking abstracts. Really interesting results. #CIBMTR study by @NinaOrfali. Planned early GSFC after allo with Thymoglobulin has an adverse effect on survival. Driven by more TRM and viral infections. #TCTM21
#EBMT2022 @MediHumdani ⭐️🌟⭐️🌟mentor, presenting outcomes of alloHCT for ALCL #CIBMTR research never sleeps!
Oral abstract 48: Real World Outcomes of #CART in pts w Sec CNS lymphoma: #CIBMTR analysis ➡️N=144, 3 LOT, 40% primary refractory ➡️2yr PFS 20%, 2yr OS 33%, NRM 5%, relapse 75%!! Grateful to @CIBMTR @ASTCT for this opportunity to present at #Tandem24 @MSKCancerCenter #MedTwitter
Quick tweetorial on how to vote #CIBMTR proposals.1 Go to your #Tandem22 app. 2 look for the @CIBMTR working committee you want to vote 3. Click “here to view”scoring sheet. 4 It will automatically pop up a new webpage. 5. Score proposals #remember 1 is exceptional 9 is poor👇🏼
Post transplant survival in Mantle cell #lymphoma #CIBMTR #LYWCIBMTR Data from @CIBMTR Summary slides
Check out my CIBMTR Acute Leukemia proposal. A yet unanswered question to one we encounter relatively frequently in clinical practice. #tandem22 #CIBMTR @ASTCT @UKMarkey @CIBMTR @UK_HealthCare
Number of transplants in US continue to grow #CIBMTR Data from 2014 @CIBMTR Summary Slides @BeTheMatch @LLSWisconsin
Amazing session at #Tandem22 looking at the history of #CIBMTR #50thanniversary and the future ahead
HGBCL-NOS: We identify another histology with relatively CAR resistant relapse. N=111, most axi-cel, 2 year OS and PFS 42% and 29%. NRM 3%. #lymsm #cibmtr BJH | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…
Refining the management of #CRS and ICANS in CAR T-cell therapy is essential as diagnostic criteria and treatment strategies continue to evolve, and ongoing research continues to further refine clinical guidelines. Read more from our coverage of the #ASTCT #CIBMTR meeting below.
The 2025 #ASTCT and #CIBMTR (Center for International Blood & Marrow Transplant Research) #TandemMeetings are underway! Be sure to catch this morning's presentation, The Role of #RWE in #Regulatory and #HTA Decision Making buff.ly/3EdvH5V #RealWorldEvidence
A CIBMTR study looked at a CAR-T called axicabtagene ciloleucel, or axi-cel. In the study, 1,300 people got axi-cel during 2017-2020. Researchers observed patients for about 2 years after treatment. Read more: cibmtr.org/Files/Patient-…
Great presentation on a very important topic by Carolina Scinke @MeeraMohanMD from MCW looking at day +21 stem boost for post CAR T cytopenia leading to early and durable recovery. Its time we do a large #CIBMTR study @RahulBanerjeeMD . #ASH24 #MMsm
Cyclophosphamide–Based GVHD Prophylaxis Reduces Outcome Disparity in Transplants @CIBMTR @JCO_ASCO @BrianShafferMD @MSKCancerCenter @MGooptu @DanaFarber @nmdp_org @GvHD_Meade @WUHemeOncFellow @DrMonzrAlMalki @cityofhope @DrStevenDevine oncodaily.com/107906.html #CIBMTR…
oncodaily.com
Cyclophosphamide–Based GVHD Prophylaxis Reduces Outcome Disparity in Transplants - OncoDaily
Cyclophosphamide–Based GVHD Prophylaxis Reduces Outcome Disparity in Transplants / Aaron Logan, Adrienne D. Briggs, Antonio M. Jimenez Jimenez, Brian C.
A 65-year-old drug. An exciting finding that reduces inequity in unrelated blood stem cell transplants. Congratulations to the researchers, clinicians and patients that got us here. #CIBMTR #NMDP #PTCy ascopubs.org/doi/10.1200/JC…
Oral abstract 48: Real World Outcomes of #CART in pts w Sec CNS lymphoma: #CIBMTR analysis ➡️N=144, 3 LOT, 40% primary refractory ➡️2yr PFS 20%, 2yr OS 33%, NRM 5%, relapse 75%!! Grateful to @CIBMTR @ASTCT for this opportunity to present at #Tandem24 @MSKCancerCenter #MedTwitter
This is very concerning as 1 month OS of 67% in AUTO HCT post COVID infection. Most HCT were done for myeloma. #COVID19 #TCTM21 #CIBMTR
Packed room at the #CIBMTR Late Effects working Committee Meeting. Thank you for your participation as we work together to improve HCT survivorship.
Great presentation on a very important topic by Carolina Scinke @MeeraMohanMD from MCW looking at day +21 stem boost for post CAR T cytopenia leading to early and durable recovery. Its time we do a large #CIBMTR study @RahulBanerjeeMD . #ASH24 #MMsm
#Tandem22 tweeps please support my #CIBMTR proposal on Mantle cell and lines of therapy prior to CAR-T. 👇👍🏼
Refining the management of #CRS and ICANS in CAR T-cell therapy is essential as diagnostic criteria and treatment strategies continue to evolve, and ongoing research continues to further refine clinical guidelines. Read more from our coverage of the #ASTCT #CIBMTR meeting below.
#EBMT2022 @MediHumdani ⭐️🌟⭐️🌟mentor, presenting outcomes of alloHCT for ALCL #CIBMTR research never sleeps!
Number of transplants in US continue to grow #CIBMTR Data from 2014 @CIBMTR Summary Slides @BeTheMatch @LLSWisconsin
Now happening: Late breaking abstracts. Really interesting results. #CIBMTR study by @NinaOrfali. Planned early GSFC after allo with Thymoglobulin has an adverse effect on survival. Driven by more TRM and viral infections. #TCTM21
Post transplant survival in Mantle cell #lymphoma #CIBMTR #LYWCIBMTR Data from @CIBMTR Summary slides
Nice @CIBMTR study of CAR-T outcomes for DLBCL in CR - @drkomanduri @SylvesterCancer @cytokinerelease @amjimenezmd @majorajay oncodaily.com/86860.html #CIBMTR #ActiveDisease #UCSF #PagerPublications #Physician
As my virtual background says... Vote for #CIBMTR proposal n#1 . Risk of subsequent neoplasms(SN) after the use PTCy for GVHD prophylaxis. SN are the leading cause of excess deaths in 5years alloHTC survivors. Its critical we address this question #TCTM21 #TCT #WomenInScienceDay
Something went wrong.
Something went wrong.
United States Trends
- 1. Luka 45K posts
- 2. #DWTS 90K posts
- 3. Clippers 12.2K posts
- 4. Lakers 31.3K posts
- 5. Robert 128K posts
- 6. Kris Dunn 1,494 posts
- 7. Jaxson Hayes 1,174 posts
- 8. #LakeShow 2,550 posts
- 9. Kawhi 4,483 posts
- 10. Alix 14.7K posts
- 11. Elaine 45.2K posts
- 12. Reaves 4,987 posts
- 13. Jordan 119K posts
- 14. Ty Lue 1,063 posts
- 15. Zubac 1,979 posts
- 16. Dylan 35.2K posts
- 17. Collar 37.6K posts
- 18. Normani 5,786 posts
- 19. Colorado State 2,232 posts
- 20. #DancingWithTheStars 2,273 posts